Empowered Patient Podcast

Matt Walz is the CEO of Trialbee which is empowering patients through a more inclusive trial process. The Trialbee Honey product provides three user experiences on top of one common data architecture linking the patient, the test sites, and the sponsors providing real-time information about enrollment and how a study is performing. The Trialbee Hive product uses real-world data to model outreach to a hyper-targeted audience.

Matt explains, "In terms of remote participation for studies, COVID brought to light the fact that there are tools and methods that have been available to allow patients to participate more and collect data more during clinical research without having to have frequent visits to a site. Not in all cases, but in a number of cases. And that also accelerated timelines to get to the point where you can seek a regulatory authority approval."

"One of the things we've done in some of our studies, and this really comes down to how you do outreach for recruitment, is we've started to look at rare diseases that have unique symptoms. And so Pompe disease, for example, has a set of rather unique characteristics. We recently recruited for Pompe disease where rather than just look for patients or try to recruit patients that have already been diagnosed but to actually do outreach based on the symptoms."

@Trialbee #ClinicalTrials #TrialRecruitment #RareDisease #COVID19

Trialbee.com

Listen to the podcast here

Matt Walz is the CEO of Trialbee which is empowering patients through a more inclusive trial process. The Trialbee Honey product provides three user experiences on top of one common data architecture linking the patient, the test sites, and the sponsors providing real-time information about enrollment and how a study is performing. The Trialbee Hive product uses real-world data to model outreach to a hyper-targeted audience.

Matt explains, "In terms of remote participation for studies, COVID brought to light the fact that there are tools and methods that have been available to allow patients to participate more and collect data more during clinical research without having to have frequent visits to a site. Not in all cases, but in a number of cases. And that also accelerated timelines to get to the point where you can seek a regulatory authority approval."

"One of the things we've done in some of our studies, and this really comes down to how you do outreach for recruitment, is we've started to look at rare diseases that have unique symptoms. And so Pompe disease, for example, has a set of rather unique characteristics. We recently recruited for Pompe disease where rather than just look for patients or try to recruit patients that have already been diagnosed but to actually do outreach based on the symptoms."

@Trialbee #ClinicalTrials #TrialRecruitment #RareDisease #COVID19

Trialbee.com

Download the transcript here

Sheeza Hussain is the Chief Commercial Officer of Biofourmis which is developing a hospital-at-home model for health systems that is even more in demand due to the stress of COVID-19 patients. In addition to acute care, Biofourmis is also applying its remote monitoring technology to post-acute and chronic care.

Sheeza explains, "When we think about hospital-at-home, we think about acute level type care-at-home. It's not about being cared for exactly as you would be in a hospital. But it's for those patients who still, for all intents and purposes, need to be monitored and need to be admitted to a hospital. But instead, they get to go home. They get monitoring equipment, they get to go to the comfort of their own bed, and they're still visited by clinicians or physicians every day in person as is a requirement for some of the reimbursement."

"So when it comes to hospital-at-home, it's about in our case, a patch and we're device agnostic. We offer a patch that the patient wears on their chest, and it is continuously capturing data, things like the single-lead ECG, heart rate, respiratory rate. And that is feeding our analytics engine and allowing us to be able to establish a personalized baseline for each and every patient."

@Biofourmis #HospitalatHome #RemoteCare #CareatHome #PatientMonitoring #PostAcute #ChronicCare #Hospitals

Biofourmis.com

Listen to the podcast here

Sheeza Hussain is the Chief Commercial Officer of Biofourmis which is developing a hospital-at-home model for health systems that is even more in demand due to the stress of COVID-19 patients. In addition to acute care, Biofourmis is also applying its remote monitoring technology to post-acute and chronic care.

Sheeza explains, "When we think about hospital-at-home, we think about acute level type care-at-home. It's not about being cared for exactly as you would be in a hospital. But it's for those patients who still, for all intents and purposes, need to be monitored and need to be admitted to a hospital. But instead, they get to go home. They get monitoring equipment, they get to go to the comfort of their own bed, and they're still visited by clinicians or physicians every day in person as is a requirement for some of the reimbursement."

"So when it comes to hospital-at-home, it's about in our case, a patch and we're device agnostic. We offer a patch that the patient wears on their chest, and it is continuously capturing data, things like the single-lead ECG, heart rate, respiratory rate. And that is feeding our analytics engine and allowing us to be able to establish a personalized baseline for each and every patient."

@Biofourmis #HospitalatHome #RemoteCare #CareatHome #PatientMonitoring #PostAcute #ChronicCare #Hospitals

Biofourmis.com

Download the transcript here

Tomer Shussman is CEO and Hila Glick, VP of Physical Therapy and Customer Experience of OneStep and we talk about the ways OneStep is set to augment PT for both patients and their physical therapists using the patient's smartphone. OneStep is a smartphone-based digital physical therapy service that provides around-the-clock dedicated physical therapy courses, clinical-grade motion analysis, and real-time feedback and progress reports of patients. Using the smartphone as the gait lab equivalent, OneStep is able to measure walking in all kinds of environments and when performing day-to-day activities.

Tomer explains, "What we are doing, and in that way, we are changing physical therapies substantially, in that we are enabling physical therapy to continue outside of the clinic. So, we augment the physical therapists, allowing them to treat more patients from the convenience of home, for both the PT and the patient. And that way, we enable the patients to, for example, exercise five minutes a day, their own time, build life-lasting habits, instead of having to drive to the clinic and then meet the PT once a week, every week."

Hila says, "While physical therapy is a practice that you do with hands-on, I was amazed to see how wonderful and meaningful results you can get with working remotely and what amazing connections and tremendous results are possible for walking and recovery when you work with a PT remotely."

@DigitalOneStep #GaitAnalysis #MotionAnalysis #PT #PhysicalTherapy #DigitalHealth

OneStep.co

Listen to the podcast here

Tomer Shussman is CEO and Hila Glick, VP of Physical Therapy and Customer Experience of OneStep and we talk about the ways OneStep is set to augment PT for both patients and their physical therapists using the patient's smartphone. OneStep is a smartphone-based digital physical therapy service that provides around-the-clock dedicated physical therapy courses, clinical-grade motion analysis, and real-time feedback and progress reports of patients. Using the smartphone as the gait lab equivalent, OneStep is able to measure walking in all kinds of environments and when performing day-to-day activities.

Tomer explains, "What we are doing, and in that way, we are changing physical therapies substantially, in that we are enabling physical therapy to continue outside of the clinic. So, we augment the physical therapists, allowing them to treat more patients from the convenience of home, for both the PT and the patient. And that way, we enable the patients to, for example, exercise five minutes a day, their own time, build life-lasting habits, instead of having to drive to the clinic and then meet the PT once a week, every week."

Hila says, "While physical therapy is a practice that you do with hands-on, I was amazed to see how wonderful and meaningful results you can get with working remotely and what amazing connections and tremendous results are possible for walking and recovery when you work with a PT remotely."

@DigitalOneStep #GaitAnalysis #MotionAnalysis #PT #PhysicalTherapy #DigitalHealth

OneStep.co

Download the transcript here

Mike Gladstone is the Global President of Inflammation & Immunology at Pfizer. We talk about conditions such as rheumatoid arthritis, irritable bowel syndrome (IBS), and atopic dermatitis (AD) and how minority patients with these conditions are often misdiagnosed.

Mike explains, "Well, it turns out that a lot of these diseases are completely unseen, or those diseases that are seen are just not well understood. And the reason why is, for instance, if I look at someone suffering from atopic dermatitis, for example, you may see some of the symptoms that they have, and those are bad enough, some of the redness and scratching and so forth. But what you don't know and what you don't see is how the patients suffer sometimes. They have the stares from others, they feel those stares, they feel the distance. They feel the judgment from others who see their condition, but it also goes much deeper than that. What you don't see for those patients is the constant itching."

"Now, Black and Hispanic children are also more likely than White children to miss school because of AD, and they're likely to report uncontrolled or longer duration AD. And despite the prevalence of skin conditions like this with minority individuals, they're underrepresented in medical dermatology textbooks and clinical research."

@Pfizer #ChronicConditions #AtopicDermatitis #Dermatology #HealthEquity #HealthInnovation #DigitalHealth #AFib

Pfizer.com

Listen to the podcast here

Mike Gladstone is the Global President of Inflammation & Immunology at Pfizer. We talk about conditions such as rheumatoid arthritis, irritable bowel syndrome (IBS), and atopic dermatitis (AD) and how minority patients with these conditions are often misdiagnosed.

Mike explains, "Well, it turns out that a lot of these diseases are completely unseen, or those diseases that are seen are just not well understood. And the reason why is, for instance, if I look at someone suffering from atopic dermatitis, for example, you may see some of the symptoms that they have, and those are bad enough, some of the redness and scratching and so forth. But what you don't know and what you don't see is how the patients suffer sometimes. They have the stares from others, they feel those stares, they feel the distance. They feel the judgment from others who see their condition, but it also goes much deeper than that. What you don't see for those patients is the constant itching."

"Now, Black and Hispanic children are also more likely than White children to miss school because of AD, and they're likely to report uncontrolled or longer duration AD. And despite the prevalence of skin conditions like this with minority individuals, they're underrepresented in medical dermatology textbooks and clinical research."

@Pfizer #ChronicConditions #AtopicDermatitis #Dermatology #HealthEquity #HealthInnovation #DigitalHealth #AFib

Pfizer.com

Download the transcript here

Kleanthis Xanthopoulos is Co-Founder and CEO of Shoreline Biosciences. He talks about the Shoreline cell therapy platform that uses standardized manufacturing of allogeneic induced pluripotent stem cells to create an effective treatment to kill tumor cells with multiple advantages over autologous T-cell therapies.

Kleanthis explains, "We are focusing specifically on two different effector cells, Natural Killers and Macrophages, and we derive them from a platform which is induced pluripotent stem cells. This gives us the ability to really engineer the NK cells and Macrophages that we derive from iPSC, so they become allogeneic standardized, meaning they can be introduced to any patient and then are targeted and specific."

"Initial clinical results are showing us that iPSC derived NK cells don't appear to have the kind of side effects that you see with T-cells. So we are very, very excited about that. And we are seeing that there's a different dimension in cell therapies that can be served very, very nicely through these allogeneic pluripotent stem cell based therapies."

After the interview, Shoreline announced it has raised $140 million in its latest fundraising round.

#ShorelineBio #ShoreBiosciences #Oncology #Immunotherapy #NKCells #iPSC #Macrophages #SanDiego

Shorelinebio.com

Listen to the podcast here

Kleanthis Xanthopoulos is Co-Founder and CEO of Shoreline Biosciences. He talks about the Shoreline cell therapy platform that uses standardized manufacturing of allogeneic induced pluripotent stem cells to create an effective treatment to kill tumor cells with multiple advantages over autologous T-cell therapies.

Kleanthis explains, "We are focusing specifically on two different effector cells, Natural Killers and Macrophages, and we derive them from a platform which is induced pluripotent stem cells. This gives us the ability to really engineer the NK cells and Macrophages that we derive from iPSC, so they become allogeneic standardized, meaning they can be introduced to any patient and then are targeted and specific."

"Initial clinical results are showing us that iPSC derived NK cells don't appear to have the kind of side effects that you see with T-cells. So we are very, very excited about that. And we are seeing that there's a different dimension in cell therapies that can be served very, very nicely through these allogeneic pluripotent stem cell based therapies."

After the interview, Shoreline announced it has raised $140 million in its latest fundraising round.

#ShorelineBio #ShoreBiosciences #Oncology #Immunotherapy #NKCells #iPSC #Macrophages #SanDiego

Shorelinebio.com

Download the transcript here